NO20092574L - Piperidinylamino-pyridaziner og deres anvendelse som raskt dissosierende dopamin-2-reseptor-antagonister - Google Patents

Piperidinylamino-pyridaziner og deres anvendelse som raskt dissosierende dopamin-2-reseptor-antagonister

Info

Publication number
NO20092574L
NO20092574L NO20092574A NO20092574A NO20092574L NO 20092574 L NO20092574 L NO 20092574L NO 20092574 A NO20092574 A NO 20092574A NO 20092574 A NO20092574 A NO 20092574A NO 20092574 L NO20092574 L NO 20092574L
Authority
NO
Norway
Prior art keywords
receptor antagonists
piperidinylamino
pyridazines
compounds
dissociating dopamine
Prior art date
Application number
NO20092574A
Other languages
English (en)
Inventor
Jose Ignacio Andres-Gil
Gregor James Macdonald
Frans Alfons Maria Van Den Keybus
Jose Manuel Bartolome-Nebreda
Michiel Luc Maria Van Gool
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092574(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20092574L publication Critical patent/NO20092574L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Den foreliggende oppfinnelsen angår 6-(piperidin-4-ylamino)pyridazin-3-karbonitriler som er raskt dissosierende Dopamin-2-reseptorantagonister, fremgangsmåter for å fremstille disse forbindelsene, farmasøytiske sammensetninger omfattende disse forbindelsene som en aktiv ingrediens. Forbindelsene er nyttige som medisiner for å behandle eller forhindre forstyrrelser i sentralnervesystemet, for eksempel schizofreni, ved å utøve an antipsykotisk effekt uten motoriske bivirkninger.
NO20092574A 2006-12-08 2009-07-07 Piperidinylamino-pyridaziner og deres anvendelse som raskt dissosierende dopamin-2-reseptor-antagonister NO20092574L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125685 2006-12-08
PCT/EP2007/063338 WO2008068277A1 (en) 2006-12-08 2007-12-05 Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists

Publications (1)

Publication Number Publication Date
NO20092574L true NO20092574L (no) 2009-09-08

Family

ID=37964744

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092574A NO20092574L (no) 2006-12-08 2009-07-07 Piperidinylamino-pyridaziner og deres anvendelse som raskt dissosierende dopamin-2-reseptor-antagonister

Country Status (28)

Country Link
US (1) US8466153B2 (no)
EP (1) EP2091938B1 (no)
JP (1) JP5255568B2 (no)
KR (1) KR101468384B1 (no)
CN (1) CN101547915B (no)
AR (1) AR064198A1 (no)
AT (1) ATE486070T1 (no)
AU (1) AU2007328897B2 (no)
BR (1) BRPI0720247A2 (no)
CA (1) CA2665924C (no)
CL (1) CL2007003556A1 (no)
CY (1) CY1112227T1 (no)
DE (1) DE602007010179D1 (no)
DK (1) DK2091938T3 (no)
EA (1) EA016654B1 (no)
ES (1) ES2354756T3 (no)
IL (1) IL199076A (no)
JO (1) JO2642B1 (no)
MX (1) MX2009005983A (no)
MY (1) MY148772A (no)
NO (1) NO20092574L (no)
NZ (1) NZ576484A (no)
PL (1) PL2091938T3 (no)
PT (1) PT2091938E (no)
SI (1) SI2091938T1 (no)
TW (1) TWI433676B (no)
UA (1) UA98940C2 (no)
WO (1) WO2008068277A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
WO2008128996A1 (en) * 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
KR20100016498A (ko) * 2007-04-23 2010-02-12 얀센 파마슈티카 엔.브이. 속해리성 도파민 2 수용체 길항제로서의 피리딘 유도체
JP5431305B2 (ja) * 2007-04-23 2014-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン２受容体アンタゴニストとしての４−アルコキシピリダジン誘導体
EP2310374B1 (en) * 2008-07-03 2012-10-31 Janssen Pharmaceutica N.V. Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists
EP2307374B1 (en) * 2008-07-31 2017-01-25 Janssen Pharmaceutica NV Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
EP4574152A1 (en) * 2023-12-22 2025-06-25 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Potassium channel activators for use in the treatment of epileptic disorders

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2341965C3 (de) * 1973-08-20 1979-01-25 C.H. Boehringer Sohn, 6507 Ingelheim 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
NO147672C (no) 1975-09-23 1983-05-25 Janssen Pharmaceutica Nv Analogifremgangsmaate for fremstilling av n-aryl-n-(1-l1-4-piperidinyl)-arylacetamider
US4197304A (en) * 1975-09-23 1980-04-08 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
EG12406A (en) * 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
DE3218482A1 (de) 1982-05-15 1983-11-17 Bayer Ag, 5090 Leverkusen Substituierte 5-trifluormethyl-1,3,4-thiadiazol-2-yloxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
GB9216298D0 (en) 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
TW406075B (en) 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
US5753679A (en) 1995-05-10 1998-05-19 Hoffmann-La Roche Inc. Benzyl-piperidine derivatives
MY116093A (en) * 1996-02-26 2003-11-28 Upjohn Co Azolyl piperazinyl phenyl oxazolidinone antimicrobials
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
AU8457298A (en) * 1997-08-15 1999-03-08 Pfizer Products Inc. 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor
KR100261139B1 (ko) 1998-01-16 2000-08-01 황준수 신규한 알릴티오피리다진 유도체 및 그의 제조방법
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
WO2002068409A1 (en) 2001-02-23 2002-09-06 Merck & Co., Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
EP1443046B1 (en) 2001-10-09 2008-12-17 Kyorin Pharmaceutical Co., Ltd. Novel 4-(2furoyl)aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same
AU2002360561A1 (en) 2001-12-11 2003-06-23 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
CA2474322A1 (en) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
AU2003203148A1 (en) 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
EP1486490A1 (en) 2002-02-28 2004-12-15 Takeda Chemical Industries, Ltd. Azole compounds
SE0201544D0 (sv) 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
JP3625214B2 (ja) * 2002-09-26 2005-03-02 株式会社マンダム 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品
BRPI0410239A (pt) 2003-05-08 2006-05-16 Kyorin Seiyaku Kk composto de 4-(2-furoil)aminopiperidina e medicamento
WO2005005779A2 (en) 2003-07-14 2005-01-20 Genesis Mining Technologies (Pty) Ltd Dual retention cutting arrangement
CA2532236C (en) 2003-07-29 2011-08-23 Novo Nordisk A/S Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
JP2007501801A (ja) 2003-08-07 2007-02-01 日本たばこ産業株式会社 ピロロ［１，２−ｂ］ピリダジン誘導体
CA2563963A1 (en) 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
CA2568524A1 (en) 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
CA2585172C (en) 2004-10-29 2014-08-12 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar
JP2008546784A (ja) 2005-06-20 2008-12-25 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
KR101117931B1 (ko) 2006-08-15 2012-04-12 에프. 호프만-라 로슈 아게 페닐, 피리딘 및 퀴놀린 유도체
CA2606658A1 (en) * 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
EP2307374B1 (en) 2008-07-31 2017-01-25 Janssen Pharmaceutica NV Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists

Also Published As

Publication number Publication date
EA016654B1 (ru) 2012-06-29
DE602007010179D1 (de) 2010-12-09
AR064198A1 (es) 2009-03-18
PT2091938E (pt) 2011-01-20
IL199076A (en) 2012-12-31
WO2008068277A1 (en) 2008-06-12
SI2091938T1 (sl) 2011-02-28
US20100076187A1 (en) 2010-03-25
DK2091938T3 (da) 2011-02-07
CN101547915B (zh) 2013-08-21
BRPI0720247A2 (pt) 2013-12-31
CY1112227T1 (el) 2015-12-09
EA200970553A1 (ru) 2009-10-30
CL2007003556A1 (es) 2008-06-13
CA2665924C (en) 2014-08-12
TW200831098A (en) 2008-08-01
NZ576484A (en) 2010-10-29
CA2665924A1 (en) 2008-06-12
JP2010511673A (ja) 2010-04-15
HK1137434A1 (en) 2010-07-30
JO2642B1 (en) 2012-06-17
ES2354756T3 (es) 2011-03-17
AU2007328897B2 (en) 2013-01-10
ATE486070T1 (de) 2010-11-15
US8466153B2 (en) 2013-06-18
MY148772A (en) 2013-05-31
KR101468384B1 (ko) 2014-12-03
CN101547915A (zh) 2009-09-30
UA98940C2 (ru) 2012-07-10
EP2091938B1 (en) 2010-10-27
AU2007328897A1 (en) 2008-06-12
JP5255568B2 (ja) 2013-08-07
EP2091938A1 (en) 2009-08-26
TWI433676B (zh) 2014-04-11
PL2091938T3 (pl) 2011-04-29
MX2009005983A (es) 2009-06-16
KR20090089858A (ko) 2009-08-24

Similar Documents

Publication Publication Date Title
NO20082350L (no) Piperidin-4-YL-pyridazin-3-ylamin derivat som rask dissosiasjon dopamin 2-reseptor antagonister
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
WO2010077883A3 (en) Antagonists of lysophosphatidic acid receptors
WO2013153479A3 (en) Indole and indazole compounds that activate ampk
WO2011041694A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011017350A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011041461A3 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
WO2010068775A3 (en) Alkyne antagonists of lysophosphatidic acid receptors
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20084007L (no) Spirokondenserte piperidiner som modulatorer av muskarinreseptorer
NO20090266L (no) Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
MX2009008616A (es) Antagonistas del receptor de dopamina 2 de rapida disociacion.
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
WO2009038385A3 (en) Novel compounds having indazole frameworks, methods for preparing the same and pharmaceutical composition comprising the same
MX2009011415A (es) Derivados de 4-alcoxipiridazina como antagonistas del receptor de dopamina 2 de rapida disociacion.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application